Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.

Althammer S, Tan TH, Spitzmüller A, Rognoni L, Wiestler T, Herz T, Widmaier M, Rebelatto MC, Kaplon H, Damotte D, Alifano M, Hammond SA, Dieu-Nosjean MC, Ranade K, Schmidt G, Higgs BW, Steele KE.

J Immunother Cancer. 2019 May 6;7(1):121. doi: 10.1186/s40425-019-0589-x.

2.

Designed Methods for the Sorting of Tertiary Lymphoid Structure-Immune Cell Populations.

Devi-Marulkar P, Kaplon H, Dieu-Nosjean MC, Lawand M.

Methods Mol Biol. 2018;1845:189-204. doi: 10.1007/978-1-4939-8709-2_11.

PMID:
30141014
3.

Development of Methods for Selective Gene Expression Profiling in Tertiary Lymphoid Structure Using Laser Capture Microdissection.

Gutierrez-Chavez C, Knockaert S, Dieu-Nosjean MC, Goc J.

Methods Mol Biol. 2018;1845:119-137. doi: 10.1007/978-1-4939-8709-2_8.

PMID:
30141011
4.

Development of Tools for the Selective Visualization and Quantification of TLS-Immune Cells on Tissue Sections.

Klein C, Devi-Marulkar P, Dieu-Nosjean MC, Germain C.

Methods Mol Biol. 2018;1845:47-69. doi: 10.1007/978-1-4939-8709-2_4.

PMID:
30141007
5.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

PMID:
29764856
6.

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Braud VM, Biton J, Becht E, Knockaert S, Mansuet-Lupo A, Cosson E, Damotte D, Alifano M, Validire P, Anjuère F, Cremer I, Girard N, Gossot D, Seguin-Givelet A, Dieu-Nosjean MC, Germain C.

Oncoimmunology. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184. eCollection 2018.

7.

Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC.

PMID:
29518341
8.

[Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?]

Kaplon H, Dieu-Nosjean MC.

Med Sci (Paris). 2018 Jan;34(1):72-78. doi: 10.1051/medsci/20183401016. Epub 2018 Jan 31. Review. French.

9.

Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?

Teillaud JL, Dieu-Nosjean MC.

Front Immunol. 2017 Jul 21;8:830. doi: 10.3389/fimmu.2017.00830. eCollection 2017. Review.

10.

Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications.

Lawand M, Déchanet-Merville J, Dieu-Nosjean MC.

Front Immunol. 2017 Jun 30;8:761. doi: 10.3389/fimmu.2017.00761. eCollection 2017. Review.

11.

Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.

Remark R, Lupo A, Alifano M, Biton J, Ouakrim H, Stefani A, Cremer I, Goc J, Régnard JF, Dieu-Nosjean MC, Damotte D.

Oncoimmunology. 2016 Dec 8;5(12):e1255394. doi: 10.1080/2162402X.2016.1255394. eCollection 2016.

12.

Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.

Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC.

Front Immunol. 2016 Oct 3;7:407. eCollection 2016. Review.

13.

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D.

Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412.

PMID:
27299180
14.

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.

Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C.

Immunol Rev. 2016 May;271(1):260-75. doi: 10.1111/imr.12405. Review.

PMID:
27088920
15.

Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.

Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Adv Immunol. 2016;130:95-190. doi: 10.1016/bs.ai.2015.12.002. Epub 2016 Jan 29. Review.

PMID:
26923001
16.

Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I.

Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3.

17.

Cancer immune contexture and immunotherapy.

Becht E, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Curr Opin Immunol. 2016 Apr;39:7-13. doi: 10.1016/j.coi.2015.11.009. Epub 2015 Dec 17. Review.

PMID:
26708937
18.

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.

Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW.

Oncoimmunology. 2015 Jun 1;4(12):e1051922. eCollection 2015 Dec.

19.

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity.

Germain C, Gnjatic S, Dieu-Nosjean MC.

Front Immunol. 2015 Feb 23;6:67. doi: 10.3389/fimmu.2015.00067. eCollection 2015. Review.

20.

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.

Giraldo NA, Becht E, Pagès F, Skliris G, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, Lupo A, Alifano M, Damotte D, Cazes A, Triebel F, Freeman GJ, Dieu-Nosjean MC, Oudard S, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2015 Jul 1;21(13):3031-40. doi: 10.1158/1078-0432.CCR-14-2926. Epub 2015 Feb 16.

21.

Tertiary lymphoid structures in cancer and beyond.

Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH.

Trends Immunol. 2014 Nov;35(11):571-80. doi: 10.1016/j.it.2014.09.006. Epub 2014 Oct 22. Review.

PMID:
25443495
22.

The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Powell CA, Altorki NK, Merad M, Gnjatic S.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90. doi: 10.1164/rccm.201409-1671PP. Review.

23.

Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer.

Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, Goc J, Biton J, Ouakrim H, Cremer I, Dieu-Nosjean MC, Damotte D.

PLoS One. 2014 Sep 19;9(9):e106914. doi: 10.1371/journal.pone.0106914. eCollection 2014.

24.

Shaping of an effective immune microenvironment to and by cancer cells.

Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Cancer Immunol Immunother. 2014 Oct;63(10):991-7. doi: 10.1007/s00262-014-1590-3. Epub 2014 Aug 12. Review.

PMID:
25112529
25.

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses.

Goc J, Fridman WH, Hammond SA, Sautès-Fridman C, Dieu-Nosjean MC.

Oncoimmunology. 2014 May 29;3:e28976. eCollection 2014.

26.

TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer.

Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, Younes M, Dieu-Nosjean MC, Fridman WH, Sautès-Fridman C, Cremer I.

Cancer Res. 2014 Sep 15;74(18):5008-18. doi: 10.1158/0008-5472.CAN-13-2698. Epub 2014 Jul 29.

27.

The immune microenvironment: a major player in human cancers.

Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C.

Int Arch Allergy Immunol. 2014;164(1):13-26. doi: 10.1159/000362332. Epub 2014 May 13. Review.

PMID:
24852691
28.

The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.

Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, Charpentier MC, Bain S, Marmey B, Bonjour P, Biton J, Cremer I, Dieu-Nosjean MC, Sautès-Fridman C, Régnard JF, Laurent-Puig P, Alifano M, Damotte D.

Chest. 2014 Sep;146(3):633-643. doi: 10.1378/chest.13-2499.

PMID:
24676429
29.

Characteristics of tertiary lymphoid structures in primary cancers.

Goc J, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Oncoimmunology. 2013 Dec 1;2(12):e26836. Epub 2013 Oct 22. Review.

30.

Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.

Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. doi: 10.1164/rccm.201309-1611OC.

PMID:
24484236
31.

Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23.

32.

Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.

Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, Fléjou JF, Gibault L, Verkarre V, Régnard JF, Pagès ON, Oudard S, Mlecnik B, Sautès-Fridman C, Fridman WH, Damotte D.

Clin Cancer Res. 2013 Aug 1;19(15):4079-91. doi: 10.1158/1078-0432.CCR-12-3847. Epub 2013 Jun 19.

33.

The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation.

Gaspar K, Kukova G, Bunemann E, Buhren BA, Sonkoly E, Szollosi AG, Muller A, Savinko T, Lauerma AI, Alenius H, Kemeny L, Dieu-Nosjean MC, Stander S, Fischer JW, Ruzicka T, Zlotnik A, Szegedi A, Homey B.

J Dermatol Sci. 2013 Jul;71(1):12-21. doi: 10.1016/j.jdermsci.2013.04.011. Epub 2013 Apr 19.

PMID:
23702389
34.

The immune microenvironment of human tumors: general significance and clinical impact.

Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J.

Cancer Microenviron. 2013 Aug;6(2):117-22. doi: 10.1007/s12307-012-0124-9. Epub 2012 Oct 30.

35.

1(st) French-Israeli International Conference on B Cells and therapeutic antibodies: October 23-25, 2011 Jerusalem, Israel.

Reynaud CA, Moutel S, Dieu-Nosjean MC, Laskov R, Teillaud JL.

MAbs. 2012 Jul-Aug;4(4):426-33. doi: 10.4161/mabs.20289. Epub 2012 Jul 1. No abstract available.

36.

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E.

J Clin Invest. 2012 Mar;122(3):899-910. doi: 10.1172/JCI45817. Epub 2012 Feb 1.

37.

Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer.

de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Cancer Res. 2011 Oct 15;71(20):6391-9. doi: 10.1158/0008-5472.CAN-11-0952. Epub 2011 Sep 7.

38.

Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.

Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, André P, Dieu-Nosjean MC, Alifano M, Régnard JF, Fridman WH, Sautès-Fridman C, Cremer I.

Cancer Res. 2011 Aug 15;71(16):5412-22. doi: 10.1158/0008-5472.CAN-10-4179. Epub 2011 Jun 27.

39.

The immune microenvironments of lung and intraocular tumors.

Sautès-Fridman C, Dieu-Nosjean MC, Damotte D, Fisson S, Fridman WH.

Bull Cancer. 2011 Jun;98(6):58-61. doi: 10.1684/bdc.2011.1374.

40.

Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.

Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquère K, Badoual C, Damotte D, Validire P, Maubec E, Delongchamps NB, Cazes A, Gibault L, Garcette M, Dieu-Nosjean MC, Zerbib M, Avril MF, Prévost-Blondel A, Randriamampita C, Trautmann A, Bercovici N.

PLoS One. 2011 Mar 7;6(3):e17621. doi: 10.1371/journal.pone.0017621.

41.

Tumor microenvironment is multifaceted.

Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean MC.

Cancer Metastasis Rev. 2011 Mar;30(1):13-25. doi: 10.1007/s10555-011-9279-y. Review.

PMID:
21271351
42.

Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis.

Thaunat O, Patey N, Caligiuri G, Gautreau C, Mamani-Matsuda M, Mekki Y, Dieu-Nosjean MC, Eberl G, Ecochard R, Michel JB, Graff-Dubois S, Nicoletti A.

J Immunol. 2010 Jul 1;185(1):717-28. doi: 10.4049/jimmunol.0903589. Epub 2010 Jun 4.

43.

Immune infiltration in human cancer: prognostic significance and disease control.

Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pagès F, Tartour E, Sautès-Fridman C.

Curr Top Microbiol Immunol. 2011;344:1-24. doi: 10.1007/82_2010_46. Review.

PMID:
20512556
44.

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH, Damotte D, Sautès-Fridman C, Cremer I.

J Clin Invest. 2010 Apr;120(4):1285-97. doi: 10.1172/JCI36551. Epub 2010 Mar 8.

45.

Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH.

Oncogene. 2010 Feb 25;29(8):1093-102. doi: 10.1038/onc.2009.416. Epub 2009 Nov 30. Review.

PMID:
19946335
46.

Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.

Martins I, Sylla K, Deshayes F, Lauriol J, Ghislin S, Dieu-Nosjean MC, Viguier M, Verola O, Charron D, Alcaide-Loridan C, Al-Daccak R.

Melanoma Res. 2009 Aug;19(4):226-37. doi: 10.1097/CMR.0b013e32832e0bc3.

PMID:
19574933
47.

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J.

J Clin Oncol. 2008 Sep 20;26(27):4410-7. doi: 10.1200/JCO.2007.15.0284.

PMID:
18802153
48.

B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.

Thaunat O, Patey N, Gautreau C, Lechaton S, Fremeaux-Bacchi V, Dieu-Nosjean MC, Cassuto-Viguier E, Legendre C, Delahousse M, Lang P, Michel JB, Nicoletti A.

Transplantation. 2008 Jun 15;85(11):1648-53. doi: 10.1097/TP.0b013e3181735723.

PMID:
18551073
49.

Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model.

Wang G, Fyhrquist-Vanni N, Wolff H, Dieu-Nosjean MC, Kemeny L, Homey B, Lauerma AI, Alenius H.

Int Arch Allergy Immunol. 2008;147(1):41-51. doi: 10.1159/000128585. Epub 2008 Apr 30.

PMID:
18446052
50.

The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes.

Doisne JM, Castaigne JG, Deruyffelaere C, Dieu-Nosjean MC, Chamot C, Alcaide-Loridan C, Charron D, Al-Daccak R.

Mol Immunol. 2008 Feb;45(3):709-18. Epub 2007 Aug 24.

PMID:
17719638

Supplemental Content

Loading ...
Support Center